OR
NAGE

Olympiad Research’s Niagen Bioscience NAGE Stock Holding History

Olympiad Research’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,865
Closed -$56K – 388
2021
Q4 		$56K Buy
+14,865
New +$80.3K 0.02% 255
2021
Q3 		– Sell
-21,069
Closed -$208K – 300
2021
Q2 		$208K Buy
21,069
+10,331
+96% +$90.1K 0.07% 224
2021
Q1 		$100K Buy
+10,738
New +$85.1K 0.04% 171
2020
Q4 		– Sell
-10,556
Closed -$42K – 365
2020
Q3 		$42K Buy
+10,556
New +$50.9K 0.02% 339

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Olympiad Research's NAGE Position: Q1 2022 in Review

Olympiad Research sold out of Niagen Bioscience (NAGE) in Q1 2022, closing a stake of 14,865 shares — an estimated $56K sold.

Olympiad Research first reported a position in NAGE in Q3 2020 and held it in 4 quarters. The position peaked at $208K in Q2 2021. 82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

  • Olympiad Research reported no remaining Niagen Bioscience position as of Q1 2022 after selling out during the quarter.
  • Olympiad Research sold 14,865 Niagen Bioscience shares in Q1 2022, an estimated $56K.
  • Olympiad Research first reported a position in Niagen Bioscience in Q3 2020 and held it in 4 quarters.
  • Olympiad Research's Niagen Bioscience position peaked at $208K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Olympiad Research's 13F filing for Q1 2022, filed 10 May 2022.